Investigators: Beth Arrowsmith, Camille Gibson, Christina Anthony, Fiona McDonald, Jan Jones, Jane Jones, Jennifer Gatens, Jennifer Kent, Krist Ewe, Lisa Montgomery, Nikki Schultz, Peter Richmond, Tanya Stoney
Pertaprime is a study designed to learn more about a new vaccine, called Pertagen®, to protect young adults against pertussis “whooping cough”. This study will be exploring the safety and immunogenicity of this new pertussis vaccine.
Pertagen® is a ‘stand-alone’ vaccine, meaning that it only vaccinates against pertussis. The vaccines currently used in Australia are always combinations of pertussis, diphtheria and tetanus vaccines, (such as BoostrixTM.). Pertagen® is the only pertussis ‘stand-alone’ vaccine currently available in the world. This could be useful if people need frequent vaccinations such as pregnant women (who are currently recommended to receive a pertussis vaccination every pregnancy) healthcare professionals and childcare workers. Furthermore, the study will look at how this vaccine is affected by which pertussis vaccine, (acellular or whole cell) that participants when they were a baby.
Approximately 210 young adults from Australia will take part in the study. We will be recruiting participants aged 18 to 25 years and will be conducting most of our recruitment within universities here in WA - including UWA, Curtin and Murdoch University.